Religare FY26 Consolidated PAT at Rs. 87.26 Cr
Religare Enterprises announced its audited financial results for Q4 and FY26, reporting a consolidated net profit of Rs. 87.26 Cr for the full year. Q4 revenue rose to Rs. 2,467.42 Cr. Subsidiaries Care Health Insurance and Religare Finvest showed strong performance.

*this image is generated using AI for illustrative purposes only.
Religare Enterprises has announced its audited financial results for the quarter and financial year ended March 31, 2026. Following a Board meeting on May 12, 2026, the company approved the standalone and consolidated results. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company subsequently published its audited standalone and consolidated financial results in the editions dated May 13, 2026 of Financial Express (English Daily) and Jansatta (Hindi Daily). The earnings call to discuss these operational and financial highlights was scheduled for May 13, 2026, at 04:00 PM IST.
Consolidated Financial Performance
For the quarter ended March 31, 2026, Religare Enterprises reported consolidated revenue from operations of Rs. 2,467.42 Cr, compared to Rs. 2,041.86 Cr in the year-ago period. The consolidated net profit for Q4 FY26 stood at Rs. 87.26 Cr, against Rs. 243.30 Cr in the corresponding quarter of the previous year. For the full year FY26, consolidated total income was Rs. 8,459.36 Cr against total expenses of Rs. 8,372.10 Cr, resulting in a full-year consolidated net profit of Rs. 87.26 Cr.
On a standalone basis, the company reported a Net Loss of Rs. 12.36 Cr for Q4 FY26 and a Net Loss of Rs. 33.92 Cr for FY26.
The following table summarises the key consolidated and standalone financial metrics:
| Metric: | Q4 FY26 | FY26 (Rs. Cr) |
|---|---|---|
| Revenue (Consolidated) | Rs. 2,467.42 Cr | 8,459.36 |
| Total Expenses (Consolidated) | — | 8,372.10 |
| Net Profit / (Loss) (Consolidated) | Rs. 87.26 Cr | 87.26 |
| Total Income (Standalone) | Rs. 3.36 Cr | 16.44 |
| Total Expenses (Standalone) | Rs. 15.72 Cr | 50.36 |
| Net Profit / (Loss) (Standalone) | Rs. (12.36) Cr | (33.92) |
Subsidiary Highlights
Care Health Insurance reported a Gross Written Premium (GWP) of Rs. 11,417 Cr for FY26, up 24% y-o-y, with a Profit Before Tax of Rs. 539 Cr. Religare Finvest Limited (RFL) reported a PAT of Rs. 138.8 Cr in FY26, a significant increase from Rs. 24 Cr in FY25, driven by improved recoveries and a CRAR of 261.9%. Religare Broking Limited (RBL) reported a total income of Rs. 373.4 Cr and a PAT of Rs. 23.1 Cr for FY26.
Key Corporate Developments
During FY26, the company allotted 19,85,816 shares at Rs. 235 per share on conversion of share warrants into equity shares, and also allotted 2,51,000 equity shares pursuant to exercise of stock options under the REL ESOP Scheme 2019. The Board approved a Scheme of Arrangement for the demerger of the financial services business of REL to Religare Finvest Limited (RFL), subject to regulatory approvals. The Reserve Bank of India withdrew all restrictions imposed under the Corrective Action Plan (CAP) on RFL with immediate effect in July 2025.
Regulatory Disclosure
In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Religare Enterprises published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 in the May 13, 2026 editions of Financial Express (English Daily) and Jansatta (Hindi Daily). The filing was signed by Anuj Jain, Company Secretary & Compliance Officer.
Historical Stock Returns for Religare Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.02% | +3.95% | +6.52% | -3.69% | +2.00% | +130.74% |
How will the proposed demerger of REL's financial services business into Religare Finvest Limited impact the consolidated revenue structure and investor valuation once regulatory approvals are secured?
Given Care Health Insurance's 24% GWP growth, what competitive pressures or regulatory changes in the health insurance sector could challenge its ability to sustain this growth trajectory in FY27?
With RFL's CRAR standing at an exceptionally high 261.9% following RBI's removal of CAP restrictions, how aggressively is management likely to redeploy capital to scale the lending business?


































